|Market Cap (Intraday)||1.45B|
|2yr Forward PE||N/A|
ImmunoGen, Inc. Stock, NASDAQ:IMGN
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.